TY - JOUR AU - Perez De Isla, L. AU - Díaz Díaz, José Luis AU - Romero, M.J. AU - Muniz-Grijalvo, O. AU - Mediavilla, J.D. AU - Argueso, R. AU - Sanchez Munoz-Torrero, J.F. AU - Rubio, P. AU - Alvarez-Banos, P. AU - Ponte, P. AU - Manas, D. AU - Suarez Gutierrez, L. AU - Cepeda, J.M. AU - Casanas, M. AU - Fuentes, F. AU - Guijarro, C. AU - Angel Barba, M. AU - Saltijeral Cerezo, A. AU - Padro, T. AU - Mata, P. PY - 2023 SN - 1524-4539 UR - http://hdl.handle.net/20.500.11940/21039 AB - Background: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque... LA - eng KW - Humans KW - Female KW - Middle Aged KW - Male KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors KW - Proprotein Convertase 9 KW - Coronary Artery Disease KW - Hypercholesterolemia KW - Plaque, Atherosclerotic KW - Hyperlipoproteinemia Type II KW - Atherosclerosis KW - Acute Coronary Syndrome KW - Treatment Outcome TI - Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study DO - 10.1161/circulationaha.122.062557 T2 - Circulation M2 - 1436 KW - AS A Coruña KW - CHUAC VL - 147 ER -